News | August 04, 2021
Dr Reddy’s relaunch Naproxen Sodium Tablets in the US
It is part of the company’s pain/analgesics portfolio of OTC products
It is part of the company’s pain/analgesics portfolio of OTC products
It is designed to tackle mental health issues
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Subscribe To Our Newsletter & Stay Updated
